# Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

Source: https://onco.cc/trials/nct04014530/  
OnCo record `nct04014530` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of pembrolizumab in colorectal cancer, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), now recruiting.

## Summary

Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study is a phase 1/2, interventional study registered as NCT04014530 by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), with a registry enrolment figure of 47 participants, started 2019-08-01 and due to reach its primary completion in 2023-06-01. Interventions recorded: Ataluren + Pembrolizumab. Conditions listed: Colorectal Cancer; Endometrium Cancer. Primary outcome: Incidence of treatment-Emergent Adverse Event and the determination of the maximum tolerable dose of Ataluren.; Objective response rate. Colorectal eligibility wording from the registry: "inaccessible by colonoscopy or CT-guided approaches or due to safety concerns) may submit an archived specimen only upon agreement from the Sponsor". Sites: Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: ATAPEMBRO
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04014530
- Phase: 1/2
- Setting: Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
- Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT04014530: https://clinicaltrials.gov/study/NCT04014530

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04014530.json